EXEL News and Press, Exelixis Inc. From 02/18/22

Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q4 2021 Earnings Call Feb 17, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q4 2021 Earnings Call Transcript

The following slide deck was published by Exelixis, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Exelixis, Inc. 2021 Q4 - Results - Earnings Call Presentation

Exelixis, Inc. (EXEL) Q4 2021 Earnings Conference Call February 17, 2022 05:00 PM ET Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer P.J. Ha...

Exelixis press release (NASDAQ:EXEL): Q4 Non-GAAP EPS of $0.35 beats by $0.19. Revenue of $451.14M (+67.0% Y/Y) beats by $94.19M. Shares +2.67%. Cabozantinib franchise achieved a significant milestone with $1.08 Billion in U.S. Net Product Revenues for the Full Year 2021, including ...

- Total Revenues of $451.1 Million for the Fourth Quarter of 2021, $1.43 Billion for the Full Year 2021 - - Cabozantinib franchise achieved a significant milestone with $1.08 Billion in U.S. Net Product Revenues for the Full Year 2021, including $302.7 Million for the Fo...

Exelixis (NASDAQ:EXEL) is scheduled to announce Q4 earnings results on Thursday, February 17th, after market close. The consensus EPS Estimate is $0.16 (+14.3% Y/Y) and the consensus Revenue Estimate is $356.95M (+32.2% Y/Y). Over the last 2 years, EXEL has beaten EPS estimates 100% of the ti...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Ipsen (OTCPK:IPSEF) said two-year follow-up data from a phase 3 CheckMate -9ER trial, showed sustained survival benefits, and health related quality of life (HRQoL) improvements with the combination of Exelixis (NASDAQ:EXEL) Cabometyx (cabozantinib) and Bristol-Myers Squib...

Updated results to be presented at ASCO GU 2022 show sustained efficacy benefits with Opdivo in combination with CABOMETYX compared to sunitinib Patients treated with Opdivo and CABOMETYX continue to report improvements in health-related quality o...

Exelixis stock remains stagnant despite strong revenue. Cabo is in a second growth phase here, that's what is keeping the stock stagnant. If it can get out and expand, I see strong potential. For further details see: Exelixis: Rangebound Forever